tradingkey.logo
tradingkey.logo
Search

MaxCyte Inc

MXCT
Add to Watchlist
1.195USD
+0.015+1.27%
Close 09-17 16:00ET
126.83MMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+1.27%

5 Days

+0.42%

1 Month

-9.47%

6 Months

+49.38%

Year to Date

-22.90%

1 Year

-20.33%

Key Figures

1.210Open
1.230High
59.85KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.06%Turnover Ratio
1.180Prev. Close
1.190Low
72.25KTurnover
LossP/E Static
0.80P/B
0.00%Div Yield TTM
-18.43%ROA
1.86552wk High
67.77Volume Ratio
-41.05MNet Profit
106.13MShares
-0.3669EPS TTM
1.21Beta
-21.30%ROE
0.64352wk Low
3.39%Amplitude
69.19%Gross Margin
126.83MMarket Cap
3.05Reward/Risk
4.37%Risk Rate
Recent
Transcripts
More news coming soon, stay tuned...

MaxCyte Inc's Score

0.07vs previous score
Forecast8.67
Financial Health6.36
Technical4.36
Valuation Dimensions7.96
Institutional Confidence7.00
Risk Assessment2.80

Media Coverage

Coverage Level

Very Low
Very High
Positive

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
4.107Target Price
+245.17%Upside Space
Current Rating2026-092026-082026-072026-062026-052026-042026-032026-02
Strong Buy33333333
Buy22222222
Hold11222222
Sell00000000
Strong Sell00000000

MaxCyte Inc Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D

Technical Indicators

Sell

Summary

Sell

Moving Average

Neutral

MaxCyte Inc Latest Earnings Call Transcripts

MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands

MaxCyte Q2 2026 revenue fell 15% to $7.3 million, while costs declined and 2026 guidance was maintained. Genentech and DTx support second-half growth.

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-0.08/-0.09
Revenue / Forecast
7.27M/6.48M

MaxCyte Inc Profile

SectorHealthcare Equipment & Supplies
Ticker SymbolMXCT
Number of employees114
CountryUnited States of America

Ownership

ShareholdersProportion
Capricorn Fund Managers Ltd7.65%
BlackRock Institutional Trust Company, N.A.6.96%
River Global Investors LLP5.13%
Vitruvian Partners LLP4.71%
Shareholder TypesProportion
Investment Advisor28.60%
Investment Advisor/Hedge Fund20.75%
Hedge Fund8.15%
Private Equity4.71%

FAQs

What is the current price of MaxCyte Inc (MXCT)?

The current price of MaxCyte Inc (MXCT) is 1.20.

What is the symbol of MaxCyte Inc?

The ticker symbol of MaxCyte Inc is MXCT.

What is the 52-week high of MaxCyte Inc?

The 52-week high of MaxCyte Inc is 1.86.

What is the 52-week low of MaxCyte Inc?

The 52-week low of MaxCyte Inc is 0.64.

What is the market capitalization of MaxCyte Inc?

The market capitalization of MaxCyte Inc is 126.83M.

Is MaxCyte Inc (MXCT) currently rated as Buy, Hold, or Sell?

According to analysts, MaxCyte Inc (MXCT) has an overall rating of Buy, with a price target of 4.11.

What is the Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT)?

The Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT) is -0.37.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.